Growth Factor Independence 1 Antagonizes a p53-Induced DNA Damage Response Pathway in Lymphoblastic Leukemia

Cancer Cell

Volumn 23, Issue 2, 2013, Pages 200-214

  Khandanpour, Cyrus ^a,c,h   Phelan, James D ^d,h   Vassen, Lothar ^a   Schütte, Judith ^e   Chen, Riyan ^a   Horman, Shane R ^d,i   Gaudreau, Marie Claude ^a,b   Krongold, Joseph ^a,f   Zhu, Jinfang ^g   Paul, William E ^g   Dührsen, Ulrich ^c   Göttgens, Bertie ^e   Grimes, H Leighton ^d   Möröy, Tarik ^a,b,f  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

^d CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f MCGILL UNIVERSITY   (Canada)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^h NATIONAL CANCER INSTITUTE   (United States)

ⁱ GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR; GROWTH FACTOR INDEPENDENCE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NOTCH1 RECEPTOR; PROTEIN BAX; PROTEIN NOXA; PROTEIN P53; PUMA PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; B CELL LYMPHOMA; CANCER GROWTH; CANCER PROGNOSIS; CELL CYCLE PROGRESSION; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA DAMAGE; DOUBLE STRANDED DNA BREAK; GENE ACTIVATION; GENE DELETION; GENE EXPRESSION; IN VIVO STUDY; LATENT PERIOD; LEUKEMOGENESIS; LYMPHATIC LEUKEMIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REPORTER GENE; SIGNAL TRANSDUCTION; T CELL LEUKEMIA; TRANSCRIPTION INITIATION; TRANSGENIC MOUSE; TUMOR REGRESSION;

EID: 84873595634     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2013.01.011     Document Type: Article

References (49)

1. Adams J.M., Harris A.W., Pinkert C.A., Corcoran L.M., Alexander W.S., Cory S., Palmiter R.D., Brinster R.L. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985, 318:533-538.
2. Bartek J., Bartkova J., Lukas J. DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene 2007, 26:7773-7779.
3. Bartkova J., Horejsí Z., Sehested M., Nesland J.M., Rajpert-De Meyts E., Skakkebaek N.E., Stucki M., Jackson S., Lukas J., Bartek J. DNA damage response mediators MDC1 and 53BP1: constitutive activation and aberrant loss in breast and lung cancer, but not in testicular germ cell tumours. Oncogene 2007, 26:7414-7422.
4. Blyth K., Terry A., Mackay N., Vaillant F., Bell M., Cameron E.R., Neil J.C., Stewart M. Runx2: a novel oncogenic effector revealed by in vivo complementation and retroviral tagging. Oncogene 2001, 20:295-302.
5. Chakraborty J., Okonta H., Bagalb H., Lee S.J., Fink B., Changanamkandat R., Duggan J. Retroviral gene insertion in breast milk mediated lymphomagenesis. Virology 2008, 377:100-109.
6. Coustan-Smith E., Mullighan C.G., Onciu M., Behm F.G., Raimondi S.C., Pei D., Cheng C., Su X., Rubnitz J.E., Basso G., et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 2009, 10:147-156.
7. Cullion K., Draheim K.M., Hermance N., Tammam J., Sharma V.M., Ware C., Nikov G., Krishnamoorthy V., Majumder P.K., Kelliher M.A. Targeting the Notch1 and mTOR pathways in a mouse T-ALL model. Blood 2009, 113:6172-6181.
8. Dabrowska M.J., Dybkaer K., Johnsen H.E., Wang B., Wabl M., Pedersen F.S. Loss of MicroRNA targets in the 3' untranslated region as a mechanism of retroviral insertional activation of growth factor independence 1. J. Virol. 2009, 83:8051-8061.
9. Di Micco R., Fumagalli M., Cicalese A., Piccinin S., Gasparini P., Luise C., Schurra C., Garre' M., Nuciforo P.G., Bensimon A., et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 2006, 444:638-642.
10. Ferrando A.A., Neuberg D.S., Staunton J., Loh M.L., Huard C., Raimondi S.C., Behm F.G., Pui C.H., Downing J.R., Gilliland D.G., et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 2002, 1:75-87.
11. Fiolka K., Hertzano R., Vassen L., Zeng H., Hermesh O., Avraham K.B., Dührsen U., Möröy T. Gfi1 and Gfi1b act equivalently in haematopoiesis, but have distinct, non-overlapping functions in inner ear development. EMBO Rep. 2006, 7:326-333.
12. Gilks C.B., Bear S.E., Grimes H.L., Tsichlis P.N. Progression of interleukin-2 (IL-2)-dependent rat T cell lymphoma lines to IL-2-independent growth following activation of a gene (Gfi-1) encoding a novel zinc finger protein. Mol. Cell. Biol. 1993, 13:1759-1768.
13. Gökbuget N., Hoelzer D. Treatment of adult acute lymphoblastic leukemia. Semin. Hematol. 2009, 46:64-75.
14. Halazonetis T.D., Gorgoulis V.G., Bartek J. An oncogene-induced DNA damage model for cancer development. Science 2008, 319:1352-1355.
15. Hameyer D., Loonstra A., Eshkind L., Schmitt S., Antunes C., Groen A., Bindels E., Jonkers J., Krimpenfort P., Meuwissen R., et al. Toxicity of ligand-dependent Cre recombinases and generation of a conditional Cre deleter mouse allowing mosaic recombination in peripheral tissues. Physiol. Genomics 2007, 31:32-41.
16. Horman S.R., Velu C.S., Chaubey A., Bourdeau T., Zhu J., Paul W.E., Gebelein B., Grimes H.L. Gfi1 integrates progenitor versus granulocytic transcriptional programming. Blood 2009, 113:5466-5475.
17. Huang J., Sengupta R., Espejo A.B., Lee M.G., Dorsey J.A., Richter M., Opravil S., Shiekhattar R., Bedford M.T., Jenuwein T., Berger S.L. p53 is regulated by the lysine demethylase LSD1. Nature 2007, 449:105-108.
18. Khandanpour C., Krongold J., Schütte J., Bouwman F., Vassen L., Gaudreau M.C., Chen R., Calero-Nieto F.J., Diamanti E., Hannah R., et al. The human GFI136N variant induces epigenetic changes at the Hoxa9 locus and accelerates K-RAS driven myeloproliferative disorder in mice. Blood 2012, 120:4006-4017.
19. Kundu M., Compton S., Garrett-Beal L., Stacy T., Starost M.F., Eckhaus M., Speck N.A., Liu P.P. Runx1 deficiency predisposes mice to T-lymphoblastic lymphoma. Blood 2005, 106:3621-3624.
20. Kurash J.K., Lei H., Shen Q., Marston W.L., Granda B.W., Fan H., Wall D., Li E., Gaudet F. Methylation of p53 by Set7/9 mediates p53 acetylation and activity in vivo. Mol. Cell 2008, 29:392-400.
21. Li H., Ji M., Klarmann K.D., Keller J.R. Repression of Id2 expression by Gfi-1 is required for B-cell and myeloid development. Blood 2010, 116:1060-1069.
22. Margolin A.A., Palomero T., Sumazin P., Califano A., Ferrando A.A., Stolovitzky G. ChIP-on-chip significance analysis reveals large-scale binding and regulation by human transcription factor oncogenes. Proc. Natl. Acad. Sci. USA 2009, 106:244-249.
23. Medyouf H., Gusscott S., Wang H., Tseng J.C., Wai C., Nemirovsky O., Trumpp A., Pflumio F., Carboni J., Gottardis M., et al. High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling. J. Exp. Med. 2011, 208:1809-1822.
24. Morcos P.A., Li Y., Jiang S. Vivo-Morpholinos: a non-peptide transporter delivers Morpholinos into a wide array of mouse tissues. Biotechniques 2008, 45:613-614. 616, 618 passim.
25. Murtaugh L.C., Stanger B.Z., Kwan K.M., Melton D.A. Notch signaling controls multiple steps of pancreatic differentiation. Proc. Natl. Acad. Sci. USA 2003, 100:14920-14925.
26. O'Neil J., Grim J., Strack P., Rao S., Tibbitts D., Winter C., Hardwick J., Welcker M., Meijerink J.P., Pieters R., et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J. Exp. Med. 2007, 204:1813-1824.
27. Palomero T., Lim W.K., Odom D.T., Sulis M.L., Real P.J., Margolin A., Barnes K.C., O'Neil J., Neuberg D., Weng A.P., et al. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc. Natl. Acad. Sci. USA 2006, 103:18261-18266.
28. Pargmann D., Yücel R., Kosan C., Saba I., Klein-Hitpass L., Schimmer S., Heyd F., Dittmer U., Möröy T. Differential impact of the transcriptional repressor Gfi1 on mature CD4+ and CD8+ T lymphocyte function. Eur. J. Immunol. 2007, 37:3551-3563.
29. Person R.E., Li F.Q., Duan Z., Benson K.F., Wechsler J., Papadaki H.A., Eliopoulos G., Kaufman C., Bertolone S.J., Nakamoto B., et al. Mutations in proto-oncogene GFI1 cause human neutropenia and target ELA2. Nat. Genet. 2003, 34:308-312.
30. Priceputu E., Bouallaga I., Zhang Y., Li X., Chrobak P., Hanna Z.S., Poudrier J., Kay D.G., Jolicoeur P. Structurally distinct ligand-binding or ligand-independent Notch1 mutants are leukemogenic but affect thymocyte development, apoptosis, and metastasis differently. J. Immunol. 2006, 177:2153-2166.
31. Saleque S., Kim J., Rooke H.M., Orkin S.H. Epigenetic regulation of hematopoietic differentiation by Gfi-1 and Gfi-1b is mediated by the cofactors CoREST and LSD1. Mol. Cell 2007, 27:562-572.
32. Scheijen B., Jonkers J., Acton D., Berns A. Characterization of pal-1, a common proviral insertion site in murine leukemia virus-induced lymphomas of c-myc and Pim-1 transgenic mice. J. Virol. 1997, 71:9-16.
33. Schmidt T., Zörnig M., Beneke R., Möröy T. MoMuLV proviral integrations identified by Sup-F selection in tumors from infected myc/pim bitransgenic mice correlate with activation of the gfi-1 gene. Nucleic Acids Res. 1996, 24:2528-2534.
34. Schmidt T., Karsunky H., Gau E., Zevnik B., Elsässer H.P., Möröy T. Zinc finger protein GFI-1 has low oncogenic potential but cooperates strongly with pim and myc genes in T-cell lymphomagenesis. Oncogene 1998, 17:2661-2667.
35. Sharma V.M., Calvo J.A., Draheim K.M., Cunningham L.A., Hermance N., Beverly L., Krishnamoorthy V., Bhasin M., Capobianco A.J., Kelliher M.A. Notch1 contributes to mouse T-cell leukemia by directly inducing the expression of c-myc. Mol. Cell. Biol. 2006, 26:8022-8031.
36. Spooner C.J., Cheng J.X., Pujadas E., Laslo P., Singh H. A recurrent network involving the transcription factors PU.1 and Gfi1 orchestrates innate and adaptive immune cell fates. Immunity 2009, 31:576-586.
37. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., Mesirov J.P. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 2005, 102:15545-15550.
38. Thompson B.J., Buonamici S., Sulis M.L., Palomero T., Vilimas T., Basso G., Ferrando A., Aifantis I. The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J. Exp. Med. 2007, 204:1825-1835.
39. Uren A.G., Kool J., Matentzoglu K., de Ridder J., Mattison J., van Uitert M., Lagcher W., Sie D., Tanger E., Cox T., et al. Large-scale mutagenesis in p19(ARF)- and p53-deficient mice identifies cancer genes and their collaborative networks. Cell 2008, 133:727-741.
40. Van Vlierberghe P., van Grotel M., Tchinda J., Lee C., Beverloo H.B., van der Spek P.J., Stubbs A., Cools J., Nagata K., Fornerod M., et al. The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia. Blood 2008, 111:4668-4680.
41. Velu C.S., Baktula A.M., Grimes H.L. Gfi1 regulates miR-21 and miR-196b to control myelopoiesis. Blood 2009, 113:4720-4728.
42. Weng A.P., Ferrando A.A., Lee W., Morris J.P., Silverman L.B., Sanchez-Irizarry C., Blacklow S.C., Look A.T., Aster J.C. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004, 306:269-271.
43. Weng A.P., Millholland J.M., Yashiro-Ohtani Y., Arcangeli M.L., Lau A., Wai C., Del Bianco C., Rodriguez C.G., Sai H., Tobias J., et al. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev. 2006, 20:2096-2109.
44. West L.E., Gozani O. Regulation of p53 function by lysine methylation. Epigenomics 2011, 3:361-369.
45. Yuan Y., Zhou L., Miyamoto T., Iwasaki H., Harakawa N., Hetherington C.J., Burel S.A., Lagasse E., Weissman I.L., Akashi K., Zhang D.E. AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. Proc. Natl. Acad. Sci. USA 2001, 98:10398-10403.
46. Yücel R., Karsunky H., Klein-Hitpass L., Möröy T. The transcriptional repressor Gfi1 affects development of early, uncommitted c-Kit+ T cell progenitors and CD4/CD8 lineage decision in the thymus. J. Exp. Med. 2003, 197:831-844.
47. Zarebski A., Velu C.S., Baktula A.M., Bourdeau T., Horman S.R., Basu S., Bertolone S.J., Horwitz M., Hildeman D.A., Trent J.O., Grimes H.L. Mutations in growth factor independent-1 associated with human neutropenia block murine granulopoiesis through colony stimulating factor-1. Immunity 2008, 28:370-380.
48. Zhu J., Jankovic D., Grinberg A., Guo L., Paul W.E. Gfi-1 plays an important role in IL-2-mediated Th2 cell expansion. Proc. Natl. Acad. Sci. USA 2006, 103:18214-18219.
49. Zörnig M., Schmidt T., Karsunky H., Grzeschiczek A., Möröy T. Zinc finger protein GFI-1 cooperates with myc and pim-1 in T-cell lymphomagenesis by reducing the requirements for IL-2. Oncogene 1996, 12:1789-1801.